Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
275,000,000
-
Total 13F shares
-
166,761,354
-
Share change
-
-609,034
-
Total reported value
-
$231,855,383
-
Put/Call ratio
-
6.7%
-
Price per share
-
$1.39
-
Number of holders
-
124
-
Value change
-
-$5,171,826
-
Number of buys
-
59
-
Number of sells
-
54
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) as of Q1 2025
As of 31 Mar 2025,
Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) was held by
124 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
166,761,354 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, MORGAN STANLEY, FMR LLC, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., Octagon Capital Advisors LP, VANGUARD GROUP INC, Siren, L.L.C., and Point72 Asset Management, L.P..
This page lists
125
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.